ASHLAND Business Summary

Ashland Inc. (ASH) is a global specialty materials company that generates revenue through the development, manufacture, and distribution of high-value additives and functional ingredients. Its operations are organized into four primary business segments: Life Sciences, which provides pharmaceutical excipients and nutraceutical ingredients; Personal Care, offering biofunctionals and preservatives for skin and hair care; Specialty Additives, focusing on rheology modifiers for coatings and construction; and Intermediates, producing 1,4-butanediol (BDO) and its derivatives. Following a strategic portfolio optimization in 2025 that included the divestiture of lower-margin units like Avoca and its nutraceuticals business, the company has pivoted toward high-margin, patent-protected applications in consumer-driven markets. Ashland competes directly with global chemical giants such as Arkema, Clariant, Evonik, and Celanese, positioning itself as a premier, innovation-led solutions provider with a specific focus on sustainable and "responsible solver" technologies. The leadership team is headed by Chairman and CEO Guillermo Novo, who joined in 2019 after serving as CEO of Versum Materials and holding executive roles at Air Products and Dow Chemical. Key executives include Senior Vice President and CFO William C. Whitaker, who was appointed in July 2025 following a tenure in corporate development and treasury, and Dr. Osama M. Musa, the Senior Vice President and Chief Technology Officer. Operations are overseen by Wayne Muil, who assumed the role of SVP of Operations in late 2025 after extensive experience at Sadara Chemical and Dow. The company’s Board of Directors features a high-pedigree roster including former executives from P&G (Steven Bishop), Merck (Sanat Chattopadhyay), and Colgate-Palmolive (Suzan Harrison). Notable institutional backing is provided by BlackRock Inc., which maintains a significant ownership stake of approximately 9.9%.